Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-11

  Xia, Suhua ^a   Feng, Zhenyu ^b   Qi, Xiaowei ^c   Yin, Yuan ^c   Jin, Jianqiang ^c   Wu, Yufeng ^d   Wu, Haorong ^b   Feng, Yizhong ^b   Tao, Min ^a,e  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c JIANGNAN UNIVERSITY   (China)

^d ZHENGZHOU UNIVERSITY   (China)

^e Institute of Clinical Immunology of Jiangsu Province   (China)

Author keywords

p Akt; Pancreatic ductal adenocarcinoma; Prognosis; Sox9

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; MESSENGER RNA; PROTEIN KINASE B; TRANSCRIPTION FACTOR SOX9; SOX9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CORRELATION ANALYSIS; DISTANT METASTASIS; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION; AGED; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY;

AGED; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; SOX9 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS;

EID: 84919921760     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0358-0     Document Type: Article

References (34)

1. Pritchett J, Athwal V, Roberts N, Hanley NA, Hanley KP. Understanding the role of SOX9 in acquired diseases: lessons from development. Trends Mol Med. 2011;17(3):166–74. doi:10.1016/j.molmed.2010.12.001.
2. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell. 1994;79(6):1111–20.
3. Kawaguchi Y. Sox9 and programming of liver and pancreatic progenitors. J Clin Investig. 2013;123(5):1881–6. doi:10.1172/jci66022.
4. Piper K, Ball SG, Keeling JW, Mansoor S, Wilson DI, Hanley NA. Novel SOX9 expression during human pancreas development correlates to abnormalities in Campomelic dysplasia. Mech Dev. 2002;116(1–2):223–6.
5. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, Kuhara T, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet. 2011;43(1):34–41. doi:10.1038/ng.722.
6. Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci USA. 2007;104(6):1865–70. doi:10.1073/pnas.0609217104.
7. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012;72(5):1301–15. doi:10.1158/0008-5472.can-11-3660.
8. Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, et al. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol. 2012;29(5):3484–90. doi:10.1007/s12032-012-0267-z.
9. Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, et al. Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells. 2013;31(8):1454–66. doi:10.1002/stem.1394.
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc839.
11. Kumar A, Rajendran V, Sethumadhavan R, Purohit R. AKT kinase pathway: a leading target in cancer research. Sci World J. 2013;2013:756134. doi:10.1155/2013/756134.
12. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11(4):289–301. doi:10.1038/nrc3037.
13. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–75. doi:10.1038/nrc2656.
14. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62. doi:10.1038/nrc2664.
15. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006;13(7):933–9. doi:10.1245/aso.2006.07.011.
16. Liu J, Sun SHC, Sun SJ, Huang C, Hu HH, Jin YB, et al. Phosph-Akt1 expression is associated with a favourable prognosis in pancreatic cancer. Ann Acad Med Singap. 2010;39(7):548.
17. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(8):2846–50.
18. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011;8(1):27–33. doi:10.1038/nrgastro.2010.188.
19. Moghbeli M, Moghbeli F, Forghanifard MM, Abbaszadegan MR. Cancer stem cell detection and isolation. Med Oncol. 2014;31(9):69. doi:10.1007/s12032-014-0069-6.
20. Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma. 2009;56(5):371–8.
21. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55(88):2016–27.
22. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63(10):2649–57.
23. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16(3):259–66. doi:10.1016/j.ccr.2009.07.016.
24. Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(6):737–50. doi:10.1016/j.ccr.2012.10.025.
25. Meng F, Takaori K, Ito T, Masui T, Kawaguchi M, Kawaguchi Y, et al. Expression of SOX9 in intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2014;43(1):7–14. doi:10.1097/MPA.0b013e3182a70b2f.
26. Shroff S, Rashid A, Wang H, Katz MH, Abbruzzese JL, Fleming JB, et al. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol. 2014;45(3):456–63. doi:10.1016/j.humpath.2013.10.008.
27. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014. doi:10.1038/bjc.2014.215.
28. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA. 2013;110(17):6829–34. doi:10.1073/pnas.1217002110.
29. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ. 2014;21(1):124–35. doi:10.1038/cdd.2013.131.
30. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol. 2010;27(3):1017–22. doi:10.1007/s12032-009-9326-5.
31. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007;67(1):167–77. doi:10.1158/0008-5472.can-06-3782.
32. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 2009;69(12):5057–64. doi:10.1158/0008-5472.can-08-4287.
33. Ikegami D, Akiyama H, Suzuki A, Nakamura T, Nakano T, Yoshikawa H, et al. Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development. 2011;138(8):1507–19. doi:10.1242/dev.057802.
34. Cheng CC, Uchiyama Y, Hiyama A, Gajghate S, Shapiro IM, Risbud MV. PI3K/AKT regulates aggrecan gene expression by modulating Sox9 expression and activity in nucleus pulposus cells of the intervertebral disc. J Cell Physiol. 2009;221(3):668–76. doi:10.1002/jcp.21904.